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Erythrocyte-speciﬁc bisphosphoglycerate mutase is a trifunctional enzyme
which modulates the levels of 2,3-bisphosphoglycerate (2,3-BPG) in red blood
cells by virtue of its synthase and phosphatase activities. Low levels of
erythrocyte 2,3-BPG increase the afﬁnity of haemoglobin for oxygen, thus
limiting the release of oxygen into tissues. 2,3-BPG levels in stored blood decline
rapidly owing to the phosphatase activity of bisphosphoglycerate mutase, which
is enhanced by a fall in pH. Here, the 1.94 A˚ resolution X-ray structure of
bisphosphoglycerate mutase is presented, focusing on the dynamic nature of key
ligand-binding residues and their interaction with the inhibitor citrate. Residues
at the binding pocket are complete. In addition, the movement of key residues in
the presence and absence of ligand is described and alternative conformations
are explored. The conformation in which the ligand citrate would bind at the
substrate-binding pocket is proposed, with discussion and representations of its
orientation. The characterization of bisphosphoglycerate mutase–citrate inter-
actions will provide a framework for the design of speciﬁc inhibitors of the
phosphatase activity of this enzyme, which may limit the decline of 2,3-BPG in
stored blood.
1. Introduction
2,3-Bisphosphoglycerate (2,3-BPG) modulates oxygen transport by
binding preferentially to the deoxygenated haemoglobin tetramer,
thus reducing oxygen afﬁnity and facilitating the ofﬂoading of O2
molecules in tissues where oxygen levels are depleted. Where
2,3-BPG concentrations are low, oxygen binds to haemoglobin with
increased afﬁnity and the dissociation of O2 molecules in tissues is
inhibited (Benesch & Benesch, 1969; Berger et al., 1973). In normal
human erythrocytes the concentrations of both 2,3-BPG and
haemoglobin are 6 mM and they bind in a 1:1 molar ratio (Arnone,
1972).
The intracellular concentration of 2,3-BPG is maintained by the
erythrocyte-speciﬁc enzyme bisphosphoglycerate mutase (BPGAM),
a trifunctional enzyme that possesses mutase, synthase and phos-
phatase activities (Fothergill-Gilmore &Watson, 1989). A member of
the larger acid phosphatase superfamily, which also includes fructose-
2,6-bisphosphatase, pyrophosphatase and the 2,3-BPG-dependent
phosphoglycerate mutase (PGAM), BPGAM shares striking
sequence and structural similarity with the dimeric PGAM,
suggesting a common ancestor (Fothergill-Gilmore & Watson, 1989).
PGAM is ubiquitous in all tissues, predominantly catalysing the
interconversion of 2- and 3-phosphoglycerate (mutase activity), with
minimal synthase and phosphatase activities. In contrast, BPGAM is
present exclusively in red blood cells and in comparison with PGAM
displays an 800-fold lower mutase activity (Rose, 1982).
The normal erythrocyte concentration of 2,3-BPG can be altered
under certain conditions, including anaemia, congenital heart disease
and high altitude. These changes have been attributed to changes in
blood pH and the availability of metabolites which affect the synthase
and phosphatase activities of BPGAM (Mulquiney et al., 1999;
Mulquiney & Kuchel, 1999a,b). Of particular interest, however, is the
observation that the levels of 2,3-BPG in stored blood are reduced.
Indeed, it has been observed that current blood-storage systems
maintain a normal erythrocyte 2,3-BPG concentration of 6 mM for
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less than a week and all BPG is lost within 14 d (Raat et al., 2005). The
reduction in 2,3-BPG levels is accompanied by a decrease in
erythrocyte levels of ATP, sialic acid and NO and an increase in
‘bioreactive substances’ such as histamine, lipids and cytokines. As a
result, the shape of the erythrocyte changes, reducing the capacity of
the cell to penetrate the capillaries and to ofﬂoad its supply of oxygen
where it is needed (Arslan et al., 2005; Tinmouth & Chin-Yee, 2001).
At alkaline pH it has been shown that BPGAM favours the synthase
reaction; however, at lower pH the phosphatase reaction is dominant
(Mulquiney et al., 1999; Mulquiney & Kuchel, 1999a,b; Ho¨gman,
1998). Immediately after collection the pH of banked blood is 7.16,
but it falls to 6.73 during storage owing to a build-up of lactic acid
(Higgins & Klein, 1989). The change in pH is temperature-dependent
and it is during the period between blood collection and storage that
temperature appears to have a critical effect on pH and hence
2,3-BPG levels (Ho¨gman, 1998). The effects of temperature and pH
are linked to the phosphatase activity of BPGAM. While storage
solutions and buffers for the preservation of blood products have
been described in the literature (Ho¨gman, 1998; Higgins & Klein,
1989; Ho¨gman et al., 2002) and generally involve a citrate–dextrose
solution and other metabolites such as adenine and phosphate, the
problem of maintaining a balance between ATP and 2,3-BPG and of
prolonging the viability of stored erythrocytes remains (Higgins &
Klein, 1989; Ho et al., 2003). Detailed knowledge of the structure of
BPGAM including ligand-binding sites, catalytic residues and ligand-
induced dynamics should allow the design, analysis and structural
characterization of putative BPGAM phosphatase-speciﬁc inhibitors.
Such small-molecule inhibitors could be used as additives in stored
blood solutions, inhibiting the phosphatase activity of BPGAM
without affecting other enzyme activities or the integrity of the
erythrocyte and thereby potentially extending the shelf life of stored
blood products.
A number of structures of homologous cofactor-dependent
PGAMs isolated from a range of sources have been reported (Rigden
et al., 1999a,b; Crowhurst et al., 1999; Bond et al., 2001, 2002; Uhri-
nova et al., 2001) as well some unrelated and structurally distinct
cofactor-independent PGAMs (Jedrzejas et al., 2000; Rigden et al.,
2003; Nukui et al., 2007). The 2.5 A˚ resolution X-ray crystal structure
of human BPGAM in the absence of ligands (Wang et al., 2004) is
incomplete, with some key side chains absent, including amongst
others the binding-site residues Arg116 and Arg117. Our structure
has all residue side chains intact from residue 2 (Ser) to residue 250
(Asp). In particular, residues Arg116 and Arg117 have been
modelled, allowing a thorough inspection of the binding site and of
potential side-chain movements in the presence and absence of
ligand. In addition, a number of high-resolution structures of
BPGAM complexed with substrates/effectors have been solved
(Wang et al., 2006). Comparison of these complexes with our 1.94 A˚
unliganded structure of BPGAM revealed a large (3 A˚) movement
at the C backbone around Arg116/Arg117 and a distinctly large side-
chain rearrangement of these residues. We have also modelled citrate
into the active site of BPGAM and present isothermal titration
calorimetry data, which clearly show the binding of citrate, a red
blood cell metabolite and blood-storage additive (Ho¨gman, 1998;
Higgins & Klein, 1989; Ho¨gman et al., 2002).
2. Methods and materials
2.1. Plasmid construction
Standard protocols were used to ligate the gene encoding human
bisphosphoglycerate mutase into vector pET30b (Novagen) for
expression of protein with a C-terminal hexahistidine tag. Primers
were designed with 50-GGAATTCCATATGTCCAAGTACAAAC-
30 as the forward primer and 50-CCGCTCGAGTTTTTTAGCTTG-
TTTCACTTTTCC-30 as the reverse primer to anneal to the gene
encoding BPGAM, which was then ampliﬁed by PCR using Pfx
polymerase (Invitrogen). The PCR product was blunt-cloned into
pETBlue-1 and both strands were sequenced; the PCR product
was then subcloned into pET30b at NdeI and XhoI (New England
Biolabs) restriction sites. Correct insertion of the product was
checked by performing restriction digests and sequencing of the
coding region.
2.2. Protein expression and purification
Recombinant hexahistidine BPGAM was expressed in Escherichia
coli BL21 (DE3) (Stratagene). Cell cultures were grown with shaking
at 310 K in LB medium containing kanamycin at a concentration of
100 mg ml1. When the optical density at 600 nm reached 0.6, over-
expression of BPGAM was induced by addition of IPTG to a con-
centration of 0.4 mM. Following a further 4 h of growth, cells were
harvested by centrifugation. The cell pellet was resuspended in lysis
buffer (buffer A; 50 mM Tris–HCl pH 8.0, 300 mM NaCl, 10 mM
imidazole) and lysed by sonication on ice. Following centrifugation
(50 000g for 60 min and 277 K), the supernatant was ﬁltered and
loaded onto a nickel-Sepharose column (Vt ’ 20 ml; 1.6  10 cm;
Pharmacia). Nonspeciﬁcally bound proteins were eluted with buffer
A and BPGAM was subsequently eluted using a 200 ml imidazole
gradient (from buffer A to buffer B, consisting of 50 mM Tris–HCl
pH 8.0, 300 mM NaCl, 250 mM imidazole) with BPGAM eluting at
20% buffer B. BPGAM was judged to be >95% pure by SDS–PAGE.
The concentration of protein was determined spectrophotometrically
using an absorption coefﬁcient value of 1.63 for a 1 mg ml1 solution
at 280 nm, with a mass of 30 928 Da consistent with the amino-acid
sequence of human BPGAM plus the hexahistidine tag. The mass of
the puriﬁed protein was determined using electrospray mass spec-
trometry as described in Nairn et al. (1995).
2.3. Assay conditions
The mutase activity of BPGAM was determined at 298 K using an
enolase-coupled assay, in which the formation of PEP was monitored
at 240 mM. The 1 ml reaction vessel contained BPGAM at a con-
centration of 100 mg ml1, 30 mM Tris–HCl pH 7.0, 3 mM MgSO4,
10 mM bisphosphoglycerate and 0.4 units of enolase and the reaction
was started by the addition of 10 mM 3-PGA. The same assay was
used for inhibition studies with varying concentrations of ligand and
substrate. One enzyme unit is deﬁned as producing an increase in
absorbance of 0.1 min1.
2.4. Protein crystallization
Puriﬁed protein was buffer-exchanged into 20 mM Tris–HCl pH
7.5, 50 mM NaCl and concentrated to 30 mg ml1. Crystals were
grown by the hanging-drop method at 290 K as described by Wang et
al. (2004), with the well solution consisting of 18–22% PEG 6K,
100 mM HEPES pH 6.8–7.2. Crystals, which generally grew within
one week, were mounted on loops and ﬂash-frozen in liquid nitrogen
prior to data collection.
2.5. Data collection, processing and structure refinement
180 images were taken, each at 1 rotation, on BM14 at ESRF
Grenoble. Data were indexed, integrated, scaled and reﬁned using
MOSFLM, SCALA and REFMAC5 from CCP4 (Collaborative
structural communications
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Computational Project, Number 4, 1994). SHELX97 was used to
reﬁne side-chain occupancies (Sheldrick, 2008). The published 2.5 A˚
resolution structure of BPGAM (PDB code 1t8p; Wang et al., 2004)
was used as a model. Manual reﬁnement of the structure was
performed using Coot (Emsley & Cowtan, 2004).
2.6. Modelling citrate into BPGAM
Using the available complex structures of PGAM bound with
citrate (PDB code 1yfk; Wang et al., 2005) and of BPGAM bound
with BPG (PDB code 2hhj; Wang et al., 2006) as guides, citrate was
modelled into the binding site of BPGAM (PDB code 3nfy). Coot
(Emsley & Cowtan, 2004) was used to superimpose the PGAM–
citrate complex onto the BPGAM structure, giving a good approx-
imation of the conformation of citrate at the binding site, which was
then reﬁned by hand. This model was further reﬁned using the ligand-
docking program DOCK (Kuntz et al., 1982) by inputting the
BPGAM–BPG complex structure (PDB code 2hhj) to identify the
binding site and subsequently using citrate as the potential ligand.
2.7. Isothermal titration calorimetry
Citrate binding to BPGAM was measured using isothermal titra-
tion calorimetry (ITC) based on the method described by Nairn et al.
(2000). In these experiments, the protein concentration was typically
1.84 mg ml1 (30 mM) and the citrate concentration used for injection
was 1.182 mM. After 60 s, 1 ml ligand solution was injected into the
reaction cell, followed by a further 28  10 ml injections at 180 s
intervals. An average apparent association factor was calculated from
ﬁve independent ITC measurements.
3. Results
Crystallization of human BPGAM resulted in the formation of two
crystal forms. One of these had a rod-shaped morphology and did not
diffract. The other was a more regular cubic form that gave good
diffraction. Data were collected to 1.94 A˚ resolution. The crystallo-
graphic statistics are given in Table 1.
Main chainsA and B have been modelled into density from residue
2 (serine) to residue 250 (aspartic acid). In addition, the side chains of
certain key residues, which had been absent from chains A and B in
the previously available uncomplexed structure (Wang et al., 2004),
have been added. These include Arg116 and Arg117, which lie at the
entrance to the active site (Fig. 1).
The side chains of the surface residues Lys5 (chain A), Glu110
(chains A and B), Gln134 (chain A) and Asp237 (chain B), which
were absent from the structure of Wang et al. (2004), have also been
added.
Citrate was modelled into the entrance of the BPGAM active site
(Fig. 2). Comparison of this model with our unliganded structure
revealed a number of structural differences around proposed ligand-
binding residues, namely Arg100, Arg116 and Arg117 (Nairn et al.,
2000). Positioning citrate at the entrance to the binding site of
BPGAM resulted in signiﬁcant movement of the side chains of
Arg100, Arg116 and Arg117. The distances between citrate and the
binding-site residues of BPGAM are summarized in Table 2. These
distances compare favourably with comparable interactions in the
PGAM–citrate complex (1yfk) and the BPGAM–BPG complex
(2hhj).
Measurements of ligand occupancy at the binding site of X-ray
crystal complex structures have been well described in the literature
(Wu et al., 2001; McNae et al., 2005). This technique has been used
here to measure the occupancy of the critical ligand-binding arginine
residues. An occupancy reﬁnement of the side chain of Arg116 gives
an occupancy of 69% position 1 (directed away from the binding site,
with a distance of 8.23 A˚ between NH2 and C1 of citrate) and 31%
position 2 (directed in towards the binding site, with distances of
3.4 A˚ between NH2 and the O2 atom of citrate and of 2.67 A˚ between
NE and C1). In comparison, the distances between Arg116 and
structural communications
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Table 1
Data-collection and reﬁnement statistics for BPGAM.
Values in parentheses are for the highest resolution shell.
Data collection
X-ray source ESRF Grenoble BM14
Space group P1211
Unit-cell parameters (A˚, ) a = 38.5, b = 61.3, c = 122.7,
 = 90,  = 95.8,  = 90
Resolution range (A˚) 122.17–1.94 (2.04–1.94)
No. of reﬂections 40076
Reﬂections used 38075
Completeness 95.0 (84.9)
hI/(I)i 6.7 (2.0)
Rmerge 0.062 (0.281)
Multiplicity 3.6 (3.4)
Reﬁnement
No. of atoms 5089
No. of water molecules 1015
R factor 0.176
Rfree 0.244
B factor (Wilson plot) (A˚2) 25.49
PDB code 3nfy
Figure 1
The binding pocket of BPGAM (PDB entry 3nfy), showing amino acids Arg116,
Arg117 and Arg100 in electron density. The orientations of the side chains of these
residues differ from the orientations of the side chains of Arg116, Arg117 and
Arg100 in the BPGAM–BPG complex structure (PDB entry 2hhj), suggesting a
large degree of movement upon ligand binding.
Table 2
Distances (in A˚) from backbone N atoms of BPGAM (PDB entry 3nfy) to citrate
compared with PGAM–citrate (1yfk) and BPGAM–2,3-BPG (2hhj).
BPGAM–citrate
model
PGAM–citrate
(chain A/chain B) BPGAM–BPG
Cys(Ser)23 N—O4 2.79 2.57/3.68 2.79 (BPG O8)
Ser(Gly)24 N—O4 3.23 3.07/2.93 3.30 (BPG O8)
Ser(Gly)24 N—O3 3.09 3.12/3.31 3.24 (BPG O7)
Tyr92 N—O3 7.07 6.09/5.67 6.05 (BPG O7)
Phe22 N—O5 6.26 8.09/5.07 6.46 (BPG O5)
Arg116 N—O1 7.84 6.57/6.71 8.10 (BPG O5)
Arg117 N—O1 7.91 7.05/6.75 8.51 (BPG O5)
Arg117 N—O2 10.04 7.67/8.57
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citrate in the complex with PGAM (1yfk) are 3.79 A˚ for NH2–Cit O1
and 2.84 A˚ for NE–Cit O1. In the BPGAM–BPG structure (2hhj),
the distances between Arg116 NH2 and the three O atoms of the
2-phosphate group of 2,3-BPG are 3.13 A˚ (O13), 3.48 A˚ (O14) and
4.95 A˚ (O15). Similar distances were observed when 2,3-BPG was
present, with the 3-phosphate group, rather than the 2-phosphate
group, interacting with Arg116 NH2. A separate occupancy reﬁne-
ment of the side chain of Arg117 has also been measured as 69%
directed outwards from the binding pocket. Fig. 3 shows the alter-
native conformations of these two Arg residues.
Isothermal titration calorimetry was used to characterize the
interaction between BPGAM and the inhibitor citrate. The binding of
citrate to BPGAM produced small endothermic enthalpy changes
(Fig. 4). Following correction for the heat effects of dilution, the
titration data were found to be consistent with an average apparent
association constant Ka of 12 515M
1 (corresponding to a Kd of
80 mM). Mutase inhibition assays gave a Ki value of 4.85 mM for
citrate. This Ki value is much larger than the Kd value determined by
ITC; however, the apparent Ki value may be a reﬂection of the
complexity of the reaction mechanism (Nairn et al., 2000) rather than
the citrate–BPGAM afﬁnity.
4. Discussion
We have determined the crystal structure of human BPGAM in the
absence of any ligand to 1.94 A˚ resolution. A number of differences
between this structure and previously published lower resolution
structures were noted. In our structure all residue side chains are
present with the exception of the initiating methionine. Disordered
areas of electron density beyond residue 250 are most likely to reﬂect
the well documented ﬂexibility of residues 250–263 of the protein.
When compared with the structure of the BPGAM–BPG complex
structural communications
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Figure 3
Citrate (yellow) modelled into the binding pocket of BPGAM (PDB entry 3nfy),
with alternative liganded Arg116/Arg117 side-chain conformations (from PDB
entry 2hhj) shown in blue.
Figure 2
Comparison of citrate and BPG binding sites of BPGAM and PGAM. (a) Citrate
(yellow) modelled into the binding pocket of BPGAM (PDB entry 3nfy). (b)
Citrate–PGAM interactions (PDB entry 1yfk), with citrate shown in yellow. (c)
BPG–BPGAM interactions (PDB entry 2hhj), with BPG shown in yellow.
Figure 4
ITC analysis of citrate binding to BPGAM. Typical ITC data are shown for the
binding of citrate to BPGAM at 298 K in 30 mM Tris–HCl pH 8.0. Analysis of this
titration gave a Kd value for the BPGAM–citrate complex of 80 mM.
electronic reprint
(PDB code 2hhj; Wang et al., 2006), it is clear that movement of the
binding-site residues Arg116 and Arg117 has occurred on binding of
the substrate. These two ﬂexible side chains can be seen to assume a
conformation in which they are effectively ‘trapping’ the 2,3-BPG at
the binding site, forming hydrogen-bonded contacts. In particular,
Arg117 shows a very large movement, with the NH atoms having
moved by more than 13 A˚. An overlay of the BPGAM–BPG struc-
ture (2hhj) shows a movement of the C atom of Arg117 of 3.35 A˚
towards the opposite side of the binding pocket (occupied by Arg10,
His11 and Asn190). While the distances between Arg117 C and
His11 C, Arg10 C and Asn190 C have decreased by 2.68, 3.82 and
3.22 A˚, respectively, the distances between Arg117 and other residues
important in ligand binding remain comparable (Fig. 5). Movement
of the Arg at position 100 is also apparent. The distance between
Arg100 C and Phe22 CZ is 5.1 A˚ in the BPGAM–BPG structure,
whereas in the unliganded structure this distance is 8.29 A˚. These
large side-chain and backbone movements and the associated ligand–
residue interactions effectively close off the binding site.
Inspection of the BPGAM–BPG structure (Wang et al., 2006)
suggests that citrate could interact with BPGAM, making similar
contacts to those made by BPG. While a number of structural
features of 2,3-BPG are distinct from those of citrate, the numbers
and locations of hydrogen-bond donors and acceptors are compar-
able. We modelled citrate into our BPGAM structure (3nfy) with
direct hydrogen-bond contacts between Tyr92 OH and citrate O1,
between Asn17 OD1 and citrate O6 and O5, between Cys23 N and
citrate O4 and between Glu89 OE2 and citrate O3 and O7. This
compares well with the PGAM–citrate structure (1yfk), in which
direct hydrogen bonds are formed between Ser23 N and Ser23 OG
and citrate O4, between Asn17 OD1 and citrate O5 and between
Lys100 NZ and citrate O6. As Lys100 is substituted by an arginine in
BPGAM, it seems likely that backbone and side-chain movements
bring this Arg into hydrogen-bonding distance of citrate O6 on
binding BPGAM. Indeed, direct hydrogen-bond contacts can be seen
between Arg100 and BPG in the BPGAM–BPG structure (2hhj), in
which Arg117, Arg116, Cys23, Glu89, Asn17, Arg62, Arg10 and
Gly189 also contribute to direct hydrogen-bonded contacts.
Citrate is a known inhibitor of many central metabolic enzymes,
including 6-phosphofructokinase (Kd = 20 mM; Newsholme et al.,
1977; Ogawa & Atkinson, 1985; Colombo et al., 1975) and isocitrate
dehydrogenase (Ki = 160 mM; Popova et al., 2007). It is also an
effective inhibitor of members of the acid phosphatase superfamily,
including 6-phosphofructo-2-kinase (Ki = 35 mM for kinase activity;
Ventura et al., 1992). Our ITC measurements suggest that citrate
binds BPGAM with a Kd value of 80 mM. The signiﬁcance of this
value is supported by the Km value of 300 mM for BPG (mutase
activity of BPGAM; Ravel et al., 1997). Given that citrate and BPG
share similar size and charge properties, they are likely to form
similar multiple electrostatic interactions with the basic residues
located at the entrance to the BPGAM active site.
5. Conclusions
We have presented the X-ray crystal structure of human bisphos-
phoglycerate mutase crystallized in the absence of any ligand and
thus are able to give details of the dynamic nature of the ligand-
binding residues for the ﬁrst time. Modelling of the structure into
electron density and comparison with known structures has identiﬁed
substantial movements of side chains at the binding pocket in the
presence and absence of ligand.
The modelling of citrate into the binding pocket which we have
described in this paper was guided by the published structures of
PGAM–citrate and BPGAM–BPG (Wang et al., 2005, 2006) and we
are conﬁdent that our model will be very similar to any future
BPGAM–citrate complex which is solved. We anticipate that our
BPGAM–citrate model will be a useful tool for the design of
potential inhibitors of BPGAM phosphatase activity, although it is
clear that any useful inhibitor will have to incorporate nonpolar
features (e.g. heterocycles or hetero-substituted phenyl groups) to
allow it to cross lipid bilayers since citrate itself is predominantly a
trianion at pH 7.
It should be noted that 30% of molecules in the crystal lattice
have the side chains of Arg116 and Arg117 close to the expected
conformation in the presence of ligand. This indicates a high degree
of ﬂexibility, which will require consideration when designing
potential ligands for the active site of BPGAM.
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